Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial
- PMID: 38598229
- PMCID: PMC11007649
- DOI: 10.1001/jamadermatol.2024.0257
Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial
Abstract
Importance: There is no US Food and Drug Administration-approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options. Involvement of interleukin (IL) 23 suggests a potential therapeutic target.
Objective: To determine whether guselkumab, an IL-23p19 inhibitor, provides clinical improvement for participants with PRP and better understand gene and protein dysregulation in PRP.
Design, setting, and participants: This single-arm, investigator-initiated nonrandomized trial was conducted from October 2019 to August 2022 at a single-center academic university with participants from 8 states in the US. In total, 14 adults with moderate to severe PRP were enrolled; 12 completed the trial. Age-matched and sex-matched healthy controls provided skin and blood for proteomic and transcriptomic studies. The primary outcome was observed at 24 weeks, and additional follow-up occurred at 36 weeks.
Intervention: Guselkumab is a fully human immunoglobulin G1 λ monoclonal antibody that selectively binds and inhibits the p19 subunit of IL-23. Subcutaneous injections were given at the US Food and Drug Administration-approved dosing schedule for psoriasis over a 24-week period.
Main outcomes and measures: The primary outcome was the mean change in the Psoriasis Area Severity Index (PASI) score at week 24. Secondary outcomes included pruritus, Dermatology Life Quality Index score, clinical response at week 36, and association with transcriptomics and proteomics expression.
Results: A per-protocol analysis was performed for the cohort of 4 female and 8 male patients who had a mean (SD) age of 56.5 (18.7) years. The mean improvement in PASI score, pruritus, and Dermatology Life Quality Index score was 61.8% (P < .001), 62.3% (P = .001), and 60.2% (P < .001), respectively. Nine participants (75%) achieved a 50% improvement in PASI. Among these clinical responders, at week 36, 8 of 9 achieved PASI75, and 6 of 9 achieved PASI90. No participants had pathogenic CARD14 gene variations. There was 1 serious adverse event that was not associated with the study drug. Proteomics and gene expression profiles identified dysregulation of a predominance of inflammatory pathways (such as T helper 17 and nuclear factor κ B) in participants with PRP who later responded well to treatment with guselkumab and stronger dysregulation of keratinocyte development pathways in individuals who did not respond to guselkumab.
Conclusion and relevance: The results of this nonrandomized trial suggest that guselkumab has efficacy in treating refractory moderate to severe adult PRP.
Trial registration: ClinicalTrials.gov Identifier: NCT03975153.
Conflict of interest statement
Similar articles
-
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.JAMA Dermatol. 2020 Jun 1;156(6):668-675. doi: 10.1001/jamadermatol.2020.0932. JAMA Dermatol. 2020. PMID: 32293641 Free PMC article. Clinical Trial.
-
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.Br J Dermatol. 2022 Nov;187(5):650-658. doi: 10.1111/bjd.21708. Epub 2022 Jul 15. Br J Dermatol. 2022. PMID: 35701384 Clinical Trial.
-
Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris.Arch Dermatol Res. 2024 Jun 6;316(6):334. doi: 10.1007/s00403-024-03137-3. Arch Dermatol Res. 2024. PMID: 38844710
-
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1. Am J Clin Dermatol. 2018. PMID: 30467781 Review.
-
Updates on Pityriasis Rubra Pilaris: A Scoping Review.J Cutan Med Surg. 2024 Mar-Apr;28(2):158-166. doi: 10.1177/12034754231223159. Epub 2024 Jan 4. J Cutan Med Surg. 2024. PMID: 38174859 Free PMC article. Review.
References
-
- Haynes D, Reiter T, Velasco R, et al. . Pityriasis rrubra pilaris transcriptomics implicate T helper 17 signaling and correlate with response to ixekizumab, with distinct gene expression profiles in nonresponders. J Invest Dermatol. 2023;143(3):501-504.e1. doi:10.1016/j.jid.2022.09.005 - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials